2,3-二氨基-6-苯基吡啶 | 144563-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,3-二氨基-6-苯基吡啶
• 英文名称: 2,3-Diamino-6-phenylpyridin
• 英文别名: 2,3-diamino-6-phenylpyridine；6-phenylpyridine-2,3-diamine
• CAS: 144563-51-9
• 化学式: C₁₁H₁₁N₃
• 分子量: 185.228
• InChiKey: KWEKGHLBYYNQBW-UHFFFAOYSA-N

物化性质

• 沸点：
  397.1±42.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-二氨基-6-苯基吡啶 在 双氧水 、 三氯氧磷 作用下， 以 溶剂黄146 为溶剂， 反应 29.25h， 生成 (+/-)-2-<2-Methoxy-4-(methylsulfinyl)phenyl>-5-phenylimidazo-1H-<4,5-b>pyridin
  参考文献：
  名称：

  Nitroketenaminal, 10.Mit. Synthese von 5-Methyl- und 5-Phenyl-Sulmazol. Nitroketeneaminals, X: Synthesis of 5-Methyl- and 5-Phenyl-sulmazol

  摘要：

  DOI：

  10.1002/ardp.19923250918
• 作为产物：
  描述：

  2-氨基-3-硝基-6-苯基吡啶 在 盐酸 、 铁粉 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 以99%的产率得到2,3-二氨基-6-苯基吡啶
  参考文献：
  名称：

  EP1460067

  摘要：

  公开号：

文献信息

• Bicyclic derivative, its production and use
  申请人：Oda Tsuneo

  公开号：US20050101647A1

  公开（公告）日：2005-05-12

  The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R 1b is a C 6-10 aryl group which has substituent(s), and the like; T a is a single bond, a C 1-6 alkyl group, —CH 2 O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Z a is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C 6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.

  本发明提供了一种具有强效酪氨酸激酶抑制活性的杂环化合物，其化学式表示为：（其中，R1是具有取代基的C6-10芳基基团等；Ta是单键，C1-6烷基基团，—CH2O—等；X和Y相同或不同，每个都是氮原子，可以具有取代基等；断裂线是单键或双键；Z是氮原子或CH；W是单键，氧原子等；Q是具有取代基的C6-10芳基基团或具有取代基的芳香杂环基团）或其盐以及含有该化合物的药物组合物。
• BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1460067A1

  公开（公告）日：2004-09-22

  The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, -CH2O-, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.

  本发明提供了一种具有强效酪氨酸激酶抑制活性的杂环化合物，由式表示： (其中，R1b是具有取代基等的C6-10芳基；Ta是单键、C1-6烷基、-CH2O-等；X和Y相同或不同，且各自是可具有取代基等的氮原子；断线是单键或双键；Za是氮原子或CH；W是单键、氧原子等；Q是可能具有取代基的C6-10芳基或可能具有取代基的芳香杂环基团；或其盐和包含其的药物组合物。
• EP1460067
  申请人：——

  公开号：——

  公开（公告）日：——
• US7622479B2
  申请人：——

  公开号：US7622479B2

  公开（公告）日：2009-11-24
• [EN] PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DÉRIVÉS PYRIDYLÉS ET PYRIMIDINYLÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：MERCK & CO INC

  公开号：WO2009005638A2

  公开（公告）日：2009-01-08

  The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the pyridyl and pyrimidinyl derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the pyridyl and pyrimidinyl derivatives in vivo.